Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.

Arabi YM, Gordon AC, Derde LPG, Nichol AD, Murthy S, Beidh FA, Annane D, Swaidan LA, Beane A, Beasley R, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buxton M, Buzgau A, Cheng A, De Jong M, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Fowler R, Girard TD, Goligher EC, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Huang DT, King AJ, Lamontagne F, Lawler PR, Lewis R, Linstrum K, Litton E, Lorenzi E, Malakouti S, McAuley DF, McGlothlin A, Mcguinness S, McVerry BJ, Montgomery SK, Morpeth SC, Mouncey PR, Orr K, Parke R, Parker JC, Patanwala AE, Rowan KM, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Tong SYC, Turgeon AF, Turner AM, Van de Veerdonk FL, Zarychanski R, Green C, Berry S, Marshall JC, McArthur C, Angus DC, Webb SA, REMAP-CAP Investigators

Open source

DOI: 10.1007/s00134-021-06448-5
Published: 2021 Aug
Container: Intensive care medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00134-021-06448-5,
  title = {Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.},
  author = {Arabi YM and Gordon AC and Derde LPG and Nichol AD and Murthy S and Beidh FA and Annane D and Swaidan LA and Beane A and Beasley R and Berry LR and Bhimani Z and Bonten MJM and Bradbury CA and Brunkhorst FM and Buxton M and Buzgau A and Cheng A and De Jong M and Detry MA and Duffy EJ and Estcourt LJ and Fitzgerald M and Fowler R and Girard TD and Goligher EC and Goossens H and Haniffa R and Higgins AM and Hills TE and Horvat CM and Huang DT and King AJ and Lamontagne F and Lawler PR and Lewis R and Linstrum K and Litton E and Lorenzi E and Malakouti S and McAuley DF and McGlothlin A and Mcguinness S and McVerry BJ and Montgomery SK and Morpeth SC and Mouncey PR and Orr K and Parke R and Parker JC and Patanwala AE and Rowan KM and Santos MS and Saunders CT and Seymour CW and Shankar-Hari M and Tong SYC and Turgeon AF and Turner AM and Van de Veerdonk FL and Zarychanski R and Green C and Berry S and Marshall JC and McArthur C and Angus DC and Webb SA and REMAP-CAP Investigators},
  year = {2021},
  journal = {Intensive care medicine},
  doi = {10.1007/s00134-021-06448-5},
  url = {https://doi.org/10.1007/s00134-021-06448-5}
}

RIS

TY  - JOUR
TI  - Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
AU  - Arabi YM
AU  - Gordon AC
AU  - Derde LPG
AU  - Nichol AD
AU  - Murthy S
AU  - Beidh FA
AU  - Annane D
AU  - Swaidan LA
AU  - Beane A
AU  - Beasley R
AU  - Berry LR
AU  - Bhimani Z
AU  - Bonten MJM
AU  - Bradbury CA
AU  - Brunkhorst FM
AU  - Buxton M
AU  - Buzgau A
AU  - Cheng A
AU  - De Jong M
AU  - Detry MA
AU  - Duffy EJ
AU  - Estcourt LJ
AU  - Fitzgerald M
AU  - Fowler R
AU  - Girard TD
AU  - Goligher EC
AU  - Goossens H
AU  - Haniffa R
AU  - Higgins AM
AU  - Hills TE
AU  - Horvat CM
AU  - Huang DT
AU  - King AJ
AU  - Lamontagne F
AU  - Lawler PR
AU  - Lewis R
AU  - Linstrum K
AU  - Litton E
AU  - Lorenzi E
AU  - Malakouti S
AU  - McAuley DF
AU  - McGlothlin A
AU  - Mcguinness S
AU  - McVerry BJ
AU  - Montgomery SK
AU  - Morpeth SC
AU  - Mouncey PR
AU  - Orr K
AU  - Parke R
AU  - Parker JC
AU  - Patanwala AE
AU  - Rowan KM
AU  - Santos MS
AU  - Saunders CT
AU  - Seymour CW
AU  - Shankar-Hari M
AU  - Tong SYC
AU  - Turgeon AF
AU  - Turner AM
AU  - Van de Veerdonk FL
AU  - Zarychanski R
AU  - Green C
AU  - Berry S
AU  - Marshall JC
AU  - McArthur C
AU  - Angus DC
AU  - Webb SA
AU  - REMAP-CAP Investigators
PY  - 2021
JO  - Intensive care medicine
DO  - 10.1007/s00134-021-06448-5
UR  - https://doi.org/10.1007/s00134-021-06448-5
ER  -

APA

YM, A., AC, G., LPG, D., AD, N., S, M., FA, B., D, A., LA, S., A, B., R, B., LR, B., Z, B., MJM, B., CA, B., FM, B., M, B., A, B., A, C., M, D. J., MA, D., EJ, D., LJ, E., M, F., R, F., TD, G., EC, G., H, G., R, H., AM, H., TE, H., CM, H., DT, H., AJ, K., F, L., PR, L., R, L., K, L., E, L., E, L., S, M., DF, M., A, M., S, M., BJ, M., SK, M., SC, M., PR, M., K, O., R, P., JC, P., AE, P., KM, R., MS, S., CT, S., CW, S., M, S., SYC, T., AF, T., AM, T., FL, V. D. V., R, Z., C, G., S, B., JC, M., C, M., DC, A., SA, W., & Investigators, R. (2021). Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.. Intensive care medicine. https://doi.org/10.1007/s00134-021-06448-5

Source records

pubmed · retrieved 2026-09-26T08:02:55.794Z
europe-pmc · retrieved 2026-09-26T08:02:55.805Z
hal · retrieved 2026-09-26T08:02:55.824Z